S&P Futures
4,260.50+4.50(+0.11%)Dow Futures
34,201.00+119.00(+0.35%)Nasdaq Futures
14,360.75+6.50(+0.05%)
Tyme Technologies, Inc. (TYME)
Chart Events
Performance Outlook
| Previous Close | 1.3200 |
| Open | 1.3300 |
| Bid | 0.0000 x 21500 |
| Ask | 0.0000 x 3200 |
| Day's Range | 1.2900 - 1.3600 |
| 52 Week Range | 0.8500 - 4.9900 |
| Volume | 1,746,834 |
| Avg. Volume | 2,866,979 |
| Market Cap | 222.147M |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2160 |
| Earnings Date | Aug 10, 2021 - Aug 16, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
Fair Value
Related Research
- Insider Monkey
Here is What Hedge Funds Think About Tyme Technologies, Inc. (TYME)
At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of March 31st. In this […]
- Simply Wall St.
Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results
Tyme Technologies, Inc. (Nasdaq:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reported its conclusions from its recently conducted comprehensive strategic review and its fourth quarter and fiscal year 2021 financial results.
